- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
June 29th, 2010
Venture capitalists and their limited partners have long bemoaned lackluster returns and the lengthening time until exits for portfolio companies. Publicly held venture firm Harris & Harris Group has gotten tired of waiting, and said it plans to invest more in public companies in a bid to make faster returns.
Since 2002, Harris & Harris has focused on backing companies with products based on nanotechnology or microsystems. Its private-company portfolio includes Mersana Therapeutics Inc., which develops cancer therapies based on its biodegradable polymer technology, and Solazyme Inc., which uses algae to produce clean fuels, chemicals, foods and health-science products.
|Related News Press|
News and information
Heat makes electrons’ spin in magnetic superconductors April 26th, 2015
Harris & Harris Group Sponsors NYC American Heart Association's Health Sciences Innovation Investment Forum: Co-founder of Harris & Harris Group Portfolio Company TARA Biosystems to Speak About the Value of Tissue Engineering Technology April 21st, 2015
Long Island Capital Alliance Announces Participants for Brookhaven National Laboratory Technology Transfer Capital Forum on May 8: Keynote Speaker Dr. Doon Gibbs, Director of Brookhaven National Laboratory April 16th, 2015
Graphenea embarks on a new era April 16th, 2015
Arrowhead to Report Fiscal 2015 First Quarter Financial Results February 2nd, 2015
Graphenea sales more than double in 2014 January 29th, 2015